Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • ED searches Gujarat...

    ED searches Gujarat pharma firm for alleged FEMA violations

    Written by Ruby Khatun Khatun Published On 2017-08-08T09:26:11+05:30  |  Updated On 8 Aug 2017 9:26 AM IST
    ED searches Gujarat pharma firm for alleged FEMA violations

    New Delhi: The ED on Saturday conducted multiple searches against a Gujarat-based pharma company for alleged "suspicious" transactions in violation of foreign exchange laws.


    The agency searched at least 11 premises of the group, identified as Vadodara-based Sandesara Group of Companies, in Vadodara, Ahmedabad, Mumbai and Delhi under the Foreign Exchange Management Act (FEMA).


    The central probe agency, in a statement, said that the companies owned by the group were "indulging in transactions which are complex and suspicious in nature and are being routed through intermediary entities situated in and outside India".


    "Chetan Jayantilal Sandesara and Nitin Jayantilal Sandesara, owners of Sandesara Group of Companies, are suspected to be controlling more than 151 entities including seven subsidiaries outside India, of which three each are in Mauritius and the British Virgin Islands and one is in Nigeria," it said.


    The Enforcement Directorate (ED), after the searches, said it seized "100 rubber stamps of different companies with same address and fixed deposit receipts of Rs 1.8 crore".


    It added that "incriminating documents have been recovered and seized" as part of the operation that began early this morning.


    "According to available information, it is suspected that Chetan and Nitin Sandesara are suppressing income, inflating expenses of their companies in India and routing such unaccounted amounts through various bogus or paper entities," the agency alleged.


    A company of the group, Sterling Biotech, was also searched by the agency sleuths during the operation.


    "It is suspected that Sterling Biotech Limited in connivance with Dubai-based NRI Arun Pancharia and his entities perpetrated fraudulent scheme whereby Pancharia subscribed the global depositary receipt (GDR) to the tune of USD 15.39 million (of Sterling Biotech) with the subscription money availed as loan from the bank for which issuer company (SBL) itself gave the security to bank.


    "It is also suspected that Sterling Biotech Limited had been exporting co-enzyme Qten to UAE and France at highly over invoiced price," the ED said.


    The agency said, "Information has also been received in respect of 13 individuals/entities of Sandesara Group of Companies, including Sterling Biotech and Blue Mark Mercantile Private Limited, for high value suspicious transactions."


    Efforts to seek comments from Sterling Biotech did not fructify.

    allegedChetan Jayantilal SandesaraEDEnforcement DirectorateFEMAforeign exchange lawsForeign Exchange Management Actglobal depositary receiptGujaratNitin Jayantilal SandesaraNRI Arun PanchariaPharma FirmSandesara Group of Companiessearchesviolations
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok